Quality Control (QC) in Clinical Research

Detail-oriented QC that delivers well-formatted, accurate, and consistent regulatory documents every time.

Thank you for the excellent QC, which gives us great comfort in the quality of the final document.
Medical Writing Director
Midsize Pharma Sponsor

QC services at MMS come complete with innovative, streamlined processes to ensure the creation of high-quality documents, delivered on-time with fewer drafts. This eases document development for Sponsor study teams and keeps their programs running at full-strength.

With fast and adaptive QC timelines, a global presence in multiple time zones, and a commitment to quality, you can expect the highest level of satisfaction for every project.

Accurate & Consistent QC Reviews

MMS provides QC as a service (QCAS) on documents we author, or as a stand-alone service. We employ a robust QC process that operates effectively or can be adapted to meet Sponsor-specific requirements. This design ensures the accuracy and consistency of data within any clinical or scientific document.

Additionally, we check documents against templates and style guides for proper formatting and style points. Using our proven method, we can QC any clinical, non-clinical, or scientific document quickly and efficiently. Our deep expertise in QCing medical writing deliverables expands across nearly all therapeutic areas.

The MMS QC Group has expertise in a broad range of regulatory documents, including:

  • Core documents, such as clinical study protocols, informed consent forms (ICF), clinical study reports (CSR), aggregate reports and common technical document (CTD) modules
  • Less common documents, such as briefing packages and responses to global health authority questions
  • Unique documents provided by Sponsors that need bespoke QC review
24-Hour Global QC Coverage

MMS is flexible across numerous times zones. With team members across India, South Africa, and the US, we can accommodate tight timelines and short notice. Our team meets daily to properly resource the best fit team member for each document type or therapeutic area.

We have the ability to train and grow new team members quickly to accommodate a growing number of requests.

Suggested For You

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval

webinar

September 12th, 2024

No Stone Unturned: Optimizing the Use of Expedited Pathways and Oncology Center of Excellence Programs to Optimize Drug Development in Oncology

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan

regulatory intelligence

August 3rd, 2024

EMA Launches New Pilot Program for Orphan Medical Devices

perspectives

July 30th, 2024

The Critical Role of Quality Control (QC) – Medical Writing and Beyond

regulatory intelligence

July 26th, 2024

Key Decision Points for Recent Oncology Approvals

regulatory intelligence

July 24th, 2024

Comments Open for Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products

perspectives

July 23rd, 2024

PSI 2024 Ignited Conversations on External Data Sources, Requirements for Estimands, and Bayesian Methodology for Statisticians in Pharma

news

July 17th, 2024

Industry Veteran Ben Dudley Joins MMS as Chief Commercial Officer (CCO) to Drive Continued Growth for the Data-focused Clinical Research Organization